SCYNEXIS, Inc. (SCYX)
After hours:
| Previous close | 1.4400 |
| Open | 1.4800 |
| Bid | 1.5200 x 300 |
| Ask | 1.5600 x 200 |
| Day's range | 1.4800 - 1.6058 |
| 52-week range | 1.3500 - 3.8700 |
| Volume | |
| Avg. volume | 200,896 |
| Market cap | 58.518M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | 1.12 |
| EPS (TTM) | 1.3900 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.88 |
GlobeNewswireSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address sy
- GlobeNewswire
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo
- GlobeNewswire
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed
